BiotechnologyNASDAQ:SRPT
Sarepta Stock Jumps 13%, but Elevidys Safety Study Slips Five Months
CAMBRIDGE, Mass., Aug. 27, 2026, 3:16 p.m. EDT — Shares of Sarepta Therapeutics rose 12.9% to $21.98 on Thursday, trading near the session high…
Market intelligence
Latest market intelligence
Fast, evidence-led coverage of the companies and events moving global markets.
All coverage
More market stories
SRPT event dashboard · Aug. 27, 2026
Sarepta rally meets an ENHANCE timeline delay
Market snapshot: 3:16 p.m. EDT. The stock move is large; the verified registry change is procedural and includes a five-month completion delay.
SRPT price
$21.98
Range $18.78–$22.57
Day move
+12.95%
≈ $265m equity value added
Volume
5.94m
≈ 1.9× recent average
Market cap
$2.32b
Intraday snapshot
What actually changed in ENHANCE
| Registry field | Before | Aug. 26 update |
|---|---|---|
| Site footprint | Original site set | Baylor College of Medicine added |
| Recruitment | Not yet recruiting | Unchanged |
| Enrollment | 20 | Unchanged |
| Estimated start | Jul. 31, 2026 | Aug. 31, 2026 |
| Primary/final completion | Mar. 31, 2027 | Aug. 31, 2027 |
Signal quality:
No new efficacy or safety result, no first-patient milestone, no FDA decision and no new Sarepta press release. The added site is constructive; the schedule slipped.
No new efficacy or safety result, no first-patient milestone, no FDA decision and no new Sarepta press release. The added site is constructive; the schedule slipped.
Q2 revenue reset
Balance-sheet pressure points
Cash + investments
$945.0m
Debt, carrying value
$847.6m
Inventory
$1.13b
Manufacturing commitments
$428.0m
Rally amplifier vs. fundamental risk
AMPLIFIER
~27% of float sold short
~27% of float sold short
CATALYST
Baylor site added
Baylor site added
TIMELINE
Completion +5 months
Completion +5 months
SAFETY
Elevidys boxed warning
Elevidys boxed warning
DEMAND
Elevidys Q2 revenue −65%
Elevidys Q2 revenue −65%
Scenario monitor
| Path | Confirmation signal | What would challenge it |
|---|---|---|
| Bull | Recruitment begins; FDA pathway gains clarity; short covering persists | Further trial slippage or weak dosing demand |
| Base | Registry edit stays procedural; shares consolidate into the next data event | Company-specific disclosure changes the evidence set |
| Bear | Delay and safety concerns dominate; squeeze fades | Fast activation plus credible label-expansion progress |
Sources: ClinicalTrials.gov,
Sarepta Form 10-Q,
Sarepta IR, and market data snapshot at 3:16 p.m. EDT. Short-interest figures are the latest published estimate and can lag. This dashboard separates verified disclosures from market inference.
CommoditiesStock Market
Copper Nears Record Highs While 675,185 Tons Remain Tied Up Amid U.S. Tariff Standoff
Copper held close to all-time highs on Thursday, with speculation over a potential U.S. tariff drawing physical metal into domestic storage facilities. This trend…
Market / Asset / Sector
Copper near records
Snapshot: Aug. 27, 2026, 15:27 ET
Prices delayed or indicative
Prices delayed or indicative
U.S. copper
$6.58/lb
−0.25% day · +4.05% month
From August record
−3.7%
Record: $6.83/lb
COMEX stocks
675,185 t
Record · 46 daily increases
Available LME stocks
≈90,000 t
COMEX is about 7.5× larger
Why the price is elevated
Reference price is 47.25% higher year over year. The line is an indexed visual, not an intraday series.
Benchmarks and policy
| Measure | Reading | Interpretation |
|---|---|---|
| LME three-month high | $14,343/t on Aug. 25 | 1.3% below $14,527.50 record |
| U.S. import pace | 885,000 t in H1 2026 | +3% YoY; more than 2× H1 2024 |
| Potential tariff | 15% from Jan. 1, 2027 | Could increase to 30% in 2028 |
| CRU balance | 639,000 t forecast surplus | Looks balanced if U.S. stocks stay unavailable |
| Argentina–Chile pipeline | $20.7bn / 540,000 t yearly | Long-dated supply; no implementation date |
Listed exposure at 15:13 ET
| Security | Price | Day | Channel |
|---|---|---|---|
| Southern Copper (SCCO) | $217.08 | +1.56% | Miner revenue and margins |
| Global X Copper Miners ETF (COPX) | $96.34 | +0.84% | Diversified miner basket |
| Freeport-McMoRan (FCX) | $78.73 | −0.34% | Large copper producer |
Investor bridge
Copper prices transmit directly into miners' realized revenue and operating margins, while raising input costs for power grids, construction, vehicles and data centers. The current premium is driven by where inventory sits, not simply how much copper exists globally.
NASDAQ:PURRStock Market
Hyperliquid Strategies Stock Jumps 19.6% as HYPE Treasury Reaches $1.9 Billion
Hyperliquid Strategies shares jumped on Thursday after the crypto treasury company reported $305.5 million of annual net income. Most of that profit came from…
CommoditiesNYSE:CDE
Gold Remains Over $4,600 as Treasury Buybacks Spark Dollar-Debasement Trade
Gold traded above $4,600 on Thursday, with Treasury bond buybacks fueling interest in dollar-debasement trades. The metal also found backing from a weaker dollar…
Market / asset / sector
Gold above $4,600
Bullion · ETFs · miners · policy transmission
Spot: Aug. 27, 2026, 13:38 EDT
Listed exposures: Aug. 27, 2026, 13:18 EDT
Listed exposures: Aug. 27, 2026, 13:18 EDT
Spot gold
$4,609.97
+0.40% · per ounce
December futures
$4,664.40
+0.20%
GLD
$422.60
+0.30% · 5.22M shares
GDX miners
$103.73
+1.28% · 8.56M shares
Breakout, consolidation, policy test
Selected intraday/settlement observations. The series shows the Treasury-buyback breakout and subsequent consolidation, not a continuous daily close chart.
ETF demand and transmission
July inflow+$3.0BGlobal gold ETFs
ETF assets$530B+1% in July
Holdings4,068t+23 tonnes
Treasury buyback≥$4BPer long-end operation
Direct channel A weaker dollar lowers gold's price for foreign buyers; ETF inflows convert that demand into physical holdings.
Catalyst timeline
Treasury expansionLong-end maximum at least doubles.
$4,600 breaksGold reaches a three-month high.
Dollar softensBullion holds the breakout.
Warsh speaksReal-rate expectations face a reset.
Listed U.S. exposures
| Exposure | Price | Day | Volume | Role |
|---|---|---|---|---|
| GLD | $422.60 | +0.30% | 5.22M | Large physical-gold ETF |
| IAU | $86.62 | +0.29% | 2.27M | Physical-gold trust |
| GDX | $103.73 | +1.28% | 8.56M | Global miners basket |
| CDE | $22.17 | +3.40% | 20.85M | Higher-beta producer |
| BTG | $5.80 | +0.96% | 21.58M | Producer exposure |
Rate sensitivity
Gold pays no yield. Higher real rates raise its opportunity cost, while lower real rates or a weaker dollar improve relative appeal.
Market pricing cited by Reuters: 34% odds of a September rate increase and 74% odds by December. Friday's Jackson Hole speech is the immediate volatility gate.
Risk board
Real yieldsA hawkish rate repricing can reverse the breakout.
DollarCurrency strength raises bullion's cost outside the U.S.
FlowsETF redemptions can accelerate physical selling.
MinersCosts, grades and geopolitics can overwhelm gold leverage.
Sources: Reuters, U.S. Treasury, World Gold Council and U.S. market data. All time-sensitive figures are timestamped above.
NASDAQ:TTWOStock Market
Take-Two Shares Slip 2.1% With Netflix Preview of GTA VI Marking Final Launch Phase
Take-Two Interactive Software stock declined 2.12% while Rockstar Games initiated its last marketing campaign for Grand Theft Auto VI.
Product / commercial catalyst
Grand Theft Auto VI: the launch funnel
Take-Two Interactive Software · NASDAQ: TTWO
Market data: Aug. 27, 2026, 13:04 EDT
Product and company data: Aug. 27, 2026
Product and company data: Aug. 27, 2026
TTWO price
$228.50
−2.12% · −$4.95
Market value
$42.73B
~$920M erased today
GTA VI base price
$79.99
PS5 · Xbox Series X|S
FY2027 bookings
$8.0–8.2B
Midpoint +20.5% vs FY2026
Company bookings step-up
The FY2027 range is company-wide. It includes GTA VI, NBA 2K, mobile titles and other releases; it is not a GTA VI sales forecast.
Market snapshot
Day range$226.55–237.77
Volume1.52M
Analyst target$296.9522 analysts
Implied upside29.9%MarketBeat consensus
Moderate Buy Analyst targets remain sensitive to launch timing and online monetization.
Four gates between attention and recognized revenue
Netflix premierePaid-platform first window
Public video releaseYouTube and Rockstar site
Game launch$79.99 base edition
Online economicsKey long-tail valuation test
Operating bridge
| Metric | Latest | Signal |
|---|---|---|
| Q1 FY2027 bookings | $1.39B | −3% year on year; slightly above guidance |
| Recurrent consumer spending | 84% of bookings | −1% year on year |
| FY2026 bookings | $6.72B | Baseline before GTA VI launch year |
| GTA V installed base | >230M units | Proof of franchise durability |
| GTA VI pre-orders | “Unprecedented” | Management description; not yet recognized sales |
What today's move says
Search attention and the showcase are strong. The stock still fell 2.12%, suggesting investors want execution evidence, not another anticipation cycle.
At $228.50, the market discounts roughly 30% upside to the analyst target. That spread also embeds delay, launch-quality and mobile-performance risk.
Risk board
TimingAnother delay would push bookings and marketing costs across fiscal periods.
ConversionPre-orders measure intent. Cancellations and edition mix determine realized revenue.
Online modelLong-term value depends on engagement and spending after launch.
PortfolioMobile weakness can offset strength from GTA and NBA 2K.
Sources: Rockstar Games; Take-Two fiscal Q1 2027 results and pre-order release; Reuters; MarketBeat; intraday U.S. market data. Figures are as timestamped and may change.
Stock Market
U.S. 10-Year Treasury yield climbs to 4.67% ahead of Warsh’s Jackson Hole address
NEW YORK, August 27, 2026, 12:56 EDT – The yield on the benchmark U.S. 10-year Treasury increased to 4.67% as investors looked to Warsh’s…
Rates • Live market transmission
U.S. 10-Year Treasury Yield
A 4.67% benchmark keeps equity discount rates and housing costs elevated before Fed Chair Kevin Warsh speaks at Jackson Hole.
Market snapshot
Aug. 27, 2026 • 12:59 EDT
Aug. 27, 2026 • 12:59 EDT
10-year yield
4.67%
▲ about 2 bp vs. prior close
30-year mortgage
6.66%
+1 bp week/week • +10 bp year/year
Initial claims
203k
−4k from revised prior week
Next catalyst
Jackson Hole
Warsh speech • Aug. 28, 10:00 EDT
Five-session yield path
Indicative market yield; latest point is intraday.10-year yield
What moved the bond market
Claims: 203,000Layoffs stayed low. That reduced urgency for near-term easing.
Mortgage surveyFreddie Mac's 30-year rate edged up to 6.66%.
Fed communicationWarsh can reset the inflation-growth balance priced into the curve.
Transmission map
Treasury benchmark4.67%Higher risk-free hurdle
Equities & creditLower PVLong-duration cash flows are most sensitive
Households6.66%30-year mortgage benchmark
Investor sensitivity
| 10Y yield shock | Estimated note price move | Typical pressure point |
|---|---|---|
| −10 bp | ≈ +0.8% | Supports duration assets |
| Unchanged | Near 0% | Carry dominates |
| +10 bp | ≈ −0.8% | Raises discount rates |
Illustrative price effect uses roughly eight-year duration. Coupon, convexity and curve shape change actual results.
Current / historical comparison
| Measure | Current | Prior | Year ago | Read-through |
|---|---|---|---|---|
| 10-year Treasury yield | 4.67% | 4.65% | ≈4.22% | About 45 bp higher year/year |
| 30-year mortgage | 6.66% | 6.65% | 6.56% | Affordability remains constrained |
| 15-year mortgage | 5.98% | 5.95% | 5.69% | Refinancing hurdle is higher |
| Continuing claims | 1.778m | 1.796m revised | — | No abrupt layoff acceleration |
Risk monitor
The yield can reverse around oil, Treasury supply and policy headlines. Weekly claims are revised and do not measure hiring directly.
Watch Friday's policy language, the 5.17% area in the 30-year yield, and whether mortgage rates hold above 6.6%.
![Asia Stock Market Today 28/08/2026 [UPDATE: 23:59 SGT] [Warsh Rate Shock Meets Korea Chip Slump as KASE Trades Late]](https://ts2.tech/wp-content/uploads/2026/08/Asia-market-dashboard-2026-08-28-2358-1024x683.jpg "Asia Stock Market Today 28/08/2026 [UPDATE: 23:59 SGT] [Warsh Rate Shock Meets Korea Chip Slump as KASE Trades Late]")
Stock Market
Asia Stock Market Today 28/08/2026 [UPDATE: 23:59 SGT] [Warsh Rate Shock Meets Korea Chip Slump as KASE Trades Late]
Warsh Rate Shock Meets Korea Chip Slump as KASE Trades Late28/08/2026 · 23:59 SGT ASIA LATE SESSION · FRIDAY, 28 AUGUST 2026 Warsh rate…
GamingNASDAQ:MSFT
Microsoft launches $899 Xbox Series X25 in bid to gauge pricing power as console revenue drops 29%
Microsoft Corp. began taking general preorders Thursday for its $899.99 Xbox Series X25 lineup. The high-end release gauges demand following a sharp drop in…
Microsoft · NASDAQ: MSFT · Product catalyst
Xbox Series X25 tests premium pricing against a shrinking hardware base
Market data: August 27, 2026, 12:38 EDT · Financials: Microsoft FY2026 Q4 / Form 10-K
Google trend: xbox series x 25th anniversary
X25 MSRP
$899.99
U.S. launch price · Nov. 13
Premium vs Series X
+$100
12.5% over the 1TB disc model
MSFT intraday
+1.52%
$503.92 · 12:38 EDT
FY26 hardware revenue
−29%
Lower console unit volume
Premium-price ladder
U.S. recommended retail prices. The PS5 Pro carries 2TB; X25 carries 1TB and includes the X25 controller plus Halo: Campaign Evolved.
What the buyer receives
Console1TB Series X25, numbered
DesignTranslucent OG Green
ControllerX25 Special Edition
GameHalo: Campaign Evolved
Standalone game price$49.99
Standalone controller$79.99
Revenue sensitivity: undisclosed limited run
Gross sales at $899.99 before returns, channel fees and revenue recognition. Microsoft has not disclosed production volume.
Scale check
FY26 Xbox revenue−$1.7B / −7%
FY26 Xbox hardware−29%
FY26 Q4 Xbox revenue−10%
FY26 Q4 More Personal Computing$12.9B / −4%
Segment operating margin21%
250K-unit X25 scenario1.74% of one MPC quarter
The launch is more useful as an average-selling-price signal than as a Microsoft-wide earnings driver.
Stock and expectations
MSFTS&P 500Technology
Illustrative indexed path using reported open, range and latest performance; it is not tick-by-tick market data. Volume was 11.86M versus a 38.95M 65-day average.
Analyst snapshot
ConsensusBUY
Analysts55
Average target$569.45
Upside vs Aug. 26 close14.72%
Target range$400–$870
MarketScreener consensus; the wide range reflects Microsoft’s cloud and AI businesses, not Xbox alone.
Catalyst timeline
Aug. 26
Microsoft announces $899.99 price and limited preorder access.
Aug. 27
Broad preorders open in select markets at 10:00 EDT.
Oct. 20
X25 Special Edition controller launches separately.
Nov. 13
Xbox Series X25 collection launches.
Investor bridge and risks
The collection directly enters Xbox hardware revenue at a 12.5% premium to the standard 1TB Series X. A sellout would support pricing power and average selling price, but even an aggressive 250,000-unit scenario produces about $225 million of gross sales—only 1.7% of one recent More Personal Computing quarter.
Watch: production volume, sell-through speed, channel inventory, discounting before November 13 and any hardware-margin disclosure. Scarcity can create a sellout without proving mass-market demand. The 1.5% MSFT gain occurred during a broad technology rally and should not be attributed to Xbox alone.
BiotechnologyNASDAQ:CELU
Celularity Stock Soars 120% as MuseCell Projects $300 Million in Purchases
Celularity shares more than doubled after MuseCell Innovations outlined a potentially large U.S. manufacturing relationship. The stock traded at $1.94 around midday, up 120.4%.
Celularity (NASDAQ: CELU)
MuseCell manufacturing collaboration
Market data: Aug. 27, 2026, 12:22 ET
Share price$1.94+120.4%
Volume151.3M~8.3× estimated float
Market value$51.4MMicro-cap
5-year purchase estimate>$300MNon-binding
Scale of the headline
The estimate is about 5.8× current market value and 11.3× last year's revenue.
Manufacturing footprint
| Facility | 147,215 sq. ft. |
| Grade C / ISO 7 suites | 9 |
| Grade D / ISO 8 suites | 6 |
| Products in scope | MuseCells, exosomes, secretome |
| Potential jobs | >200, non-binding |
Financial baseline
| Measure | Latest disclosed |
|---|---|
| 2025 revenue | $26.6M |
| 2025 net loss | -$91.7M |
| Year-end cash | $6.2M |
| Accumulated deficit | $991.5M |
| Potential annualized purchases | >$60M |
Annualized purchases are a simple five-year average, not guidance.
Regenerative-medicine peer tape
| Ticker | Price | Day | Market value |
|---|---|---|---|
| CELU | $1.94 | +120.4% | $51.4M |
| LGVN | $6.73 | -4.3% | $211.2M |
| DYAI | $0.65 | -1.2% | $23.8M |
| MRKR | $1.48 | +2.1% | $28.0M |
What must happen next
| Stage | Evidence investors need | Risk |
|---|---|---|
| Initial project | Technology transfer and qualified process | Yield, comparability and release criteria |
| Expansion | Binding purchase orders and production volumes | $300M estimate may not convert |
| Cash flow | Revenue collection and margin disclosure | Financing and dilution |
| Listing | Compliance plan due Sept. 4 | Two overdue Form 10-Q filings |
Risk frame
The five-year purchase estimate and job figure are not commitments. No product named in the agreement has FDA approval. Celularity's latest annual report showed limited cash, a large loss and substantial doubt about continued operations.
Sources: Celularity–MuseCell announcement, Celularity FY2025 Form 10-K, Nasdaq compliance notice and U.S. market data. Figures may be rounded.
Artificial IntelligenceEarnings
Synopsys Shares Rise 10.7%, Market Cap Climbs $8.5 Billion on Upbeat AI-Driven Outlook
Shares of Synopsys climbed 10.7% as increased demand for chip design enabled the software firm to boost its yearly guidance. The stock was last…
Synopsys (NASDAQ: SNPS)
Q3 FY2026 earnings and Ansys integration
Market snapshot: Aug. 27, 2026, 12:08 ET
Share price$454.06+10.7%
Q3 revenue$2.477B+42.4% YoY
Adjusted margin41.6%14.4% GAAP
FY revenue midpoint$9.715BRaised outlook
Quarterly revenue mix
Electronic Design Automation — $1.283B / 51.8%
Ansys — $711.1M / 28.7%
Design IP — $473.8M / 19.1%
Margin bridge
$402.4M of acquired-intangible amortization and $231.6M of stock compensation widened the gap.
Guidance and cash generation
| Measure | FY2026 / Q4 range |
|---|---|
| FY revenue | $9.69B-$9.74B |
| FY adjusted EPS | $15.04-$15.10 |
| Q4 revenue | $2.53B-$2.58B |
| Q4 adjusted EPS | $4.10-$4.16 |
| FY operating cash flow | About $2.8B |
| FY free cash flow | About $2.6B |
Valuation signal
The one-day equity-value gain was about 2.9 times expected full-year Ansys revenue.
Balance sheet and investor watchlist
| Signal | Current reading | What to watch |
|---|---|---|
| Cash + short-term investments | $3.608B | Integration flexibility |
| Outstanding debt | $10.037B | Debt paydown pace |
| Recurring revenue | 82% | Renewal quality and pricing |
| Q3 operating cash flow | $813M | Conversion into free cash flow |
Risks
Ansys integration expense, acquisition-related debt, export controls and the large GAAP-to-adjusted margin gap can challenge the premium valuation. After a 10.7% rally, guidance execution matters more.
Sources: Synopsys Q3 FY2026 financial supplement and quarterly results; market data at Aug. 27, 2026, 12:08 ET. Figures may be rounded.
CryptocurrencyNASDAQ:MSTR
Strategy Stock Rises 12%, Surges Ahead of Bitcoin Four Times as BTC Hits $80,000
Strategy stock surged 12% on Thursday after bitcoin topped $80,000. The equity posted a gain nearly four times higher than the cryptocurrency's daily return.
NASDAQ: MSTR · BITCOIN TREASURY
Equity leverage returns as bitcoin clears $80,000
Market: Aug. 27, 2026, 11:53 ET
Holdings and liquidity: Aug. 23, 2026
Holdings and liquidity: Aug. 23, 2026
MSTR price
$137.95
+$14.76 · +12.0%
Bitcoin
$80,367
+$2,262 · +2.9%
Bitcoin held
840,447
4.0% of maximum supply
Dollar liquidity
$6.69B
Reserve + flexible cash
One-day return: common stock versus bitcoin
The common stock added roughly $5.2 billion of quoted value. The bitcoin reserve gained about $1.9 billion at the same snapshot.
Reserve sensitivity
Gross bitcoin value
$67.5B
Unrealized gross gain
≈$4.2B
Value change per $1,000 BTC move
≈$840M
Before debt, preferred equity, tax and other claims.
Capital structure and operating signals
| Measure | Reading | Why it matters |
|---|---|---|
| BTC acquisition cost | $63.36B / $75,385 each | Current token price sits 6.6% higher |
| USD Reserve | $5.10B | Supports dividends and interest |
| USD Cash | $1.59B | Flexible treasury deployment |
| Q2 long-term debt | $6.7B | Down 18% in the quarter |
| Q2 preferred equity | $14.4B | Senior claim to common stock |
| Q2 software revenue | $122.4M | Up 6.9% year over year |
Latest capital allocation
| Action, Aug. 17–23 | Amount | Investor interpretation |
|---|---|---|
| MSTR shares sold | 18.26M | Common-stock dilution |
| Net proceeds | $2.0065B | About $109.88 per share |
| STRC repurchase | $136.4M | Reduces preferred claim |
| USD Reserve increase | $300M | Extends obligation coverage |
| Bitcoin traded | None | 840,447 BTC unchanged |
Analyst markers
Canaccord
$175
Buy · raised Aug. 25
Bernstein
$350
Outperform · cut Aug. 26
Risk frame
MSTR’s daily gain materially exceeded bitcoin’s. That leverage can reverse. Common issuance, preferred dividends, debt service, tax changes, regulation and contraction of the equity multiple can outweigh a stable token price.
Primary data: Strategy Aug. 24 Form 8-K and Q2 2026 results. Market data timestamped above.
BiotechnologyNASDAQ:PPCB
Propanc Shares Jump 151% on PRP Pancreatic Cancer Study; Volume Soars to 79 Million
Shares of Propanc Biopharma surged over 100% on Thursday following new data for its PRP therapy in pancreatic cancer. The company said the treatment…
NASDAQ: PPCB
Propanc Biopharma — PRP signal vs. financing risk
Market data: Aug. 27, 2026, 11:41 ET
Financials: March 31, 2026
Financials: March 31, 2026
Share price
$2.69
+$1.62 · +151.4%
Intraday range
$1.15–$4.32
Opened at $3.51
Volume
78.8M
≈20× recent average
Clinical stage
Preclinical
Human efficacy not established
What triggered the move
Propanc also reported fewer liver and peritoneal metastases. It said PRP increased sensitivity to gemcitabine/nab-paclitaxel in resistant cells. These are company-reported preclinical findings.
Financial capacity
| Cash | $0.44M |
| Nine-month operating cash use | $4.08M |
| Nine-month revenue | $0 |
| Nine-month net loss | $14.29M |
| Going concern | Substantial doubt |
Company filing for the period ended March 31, 2026.
Milestone map
NowPreclinical PRP package; GMP manufacturing and bioanalytical work.
Q4 2026Planned Australian clinical-trial application.
Phase 1bOpen-label dose escalation and expansion; up to 40 advanced solid-tumor patients.
Read-throughSafety, tolerability and dose selection come before any persuasive human efficacy signal.
Investor checklist
| Signal | Why it matters | Next verification |
|---|---|---|
| Preclinical efficacy | Large reported effect created attention | Independent reproduction and full dataset |
| Regulatory execution | Unlocks first human dosing | Clinical-trial application acceptance |
| Manufacturing | Required for dosing consistency | GMP batch completion and release |
| Financing | No revenue and limited cash | Funding terms, dilution and runway |
| Analyst coverage | No broad consensus located | Institutional initiation or published estimates |
Risk frame
Animal-model success frequently fails to translate into patients. PRP has not established human safety or efficacy. Regulatory delay, manufacturing problems, thin trading liquidity and equity financing could reverse Thursday’s gain quickly.
Sources: Propanc releases dated Aug. 18 and Aug. 27, 2026; Propanc Form 10-Q for March 31, 2026; market data at 11:41 ET.
NASDAQ:WENStock Market
Wendy’s shares drop 12.9% as Trian exit wipes out takeover premium
Wendy's stock dropped 12.9% after its top shareholder withdrew from a potential acquisition. The decline wiped out nearly the entire bid-fueled surge seen in…
NASDAQ: WEN · control-premium reversal
Wendy's investor dashboard
Company
Stock move
Take-private speculation
Market data: Aug. 27, 2026
11:27 a.m. EDT
11:27 a.m. EDT
Share price
$7.87
−12.94% · −$1.17
Market value
$1.50bn
≈−$223m today
Trian-related ownership
16.2%
No current bid plan
U.S. same-store sales
−7.0%
Q2 2026
August's takeover premium disappears
A near-15% speculation rally was reversed after Reuters reported that Trian has no current plan to pursue a take-private offer.
Trading snapshot
| Previous close | $9.04 |
| Open | $7.88 |
| Intraday high | $7.98 |
| Intraday low | $7.68 |
| Volume | 11.35m |
| Average volume | 8.96m |
| Relative volume | 1.27× |
| Trailing P/E | 11.9× |
| Annualized dividend yield | 3.6% |
Latest operating scorecard
| Q2 2026 | Current | YoY |
|---|---|---|
| Global systemwide sales | $3.423bn | −6.5% |
| U.S. systemwide sales | $2.876bn | −8.2% |
| Adjusted EBITDA | $124.1m | −15.4% |
| Net income | $32.6m | −40.8% |
| Adjusted EPS | $0.18 | −37.9% |
Unit economics
U.S. company-operated margin
13.8%
Down 240 basis points
Q2 2025: 16.2%
Global restaurants
7,180
U.S. 5,724 · International 1,456
Net restaurant count fell 71 in the quarter as U.S. closures outweighed international openings.
Capital allocation reset
| Measure | Before | Now |
|---|---|---|
| Quarterly dividend | $0.14 | $0.07 |
| Annualized payout | $0.56 | $0.28 |
| 2026 outlook | Issued | Withdrawn |
| Q2 repurchases | — | $0 |
The dividend cut frees capital for the turnaround but removes half of the former cash return.
Liquidity and valuation
First-half free cash flow
$120.3m
+9.9% year over year
Cash at quarter-end
$341.2m
Analyst consensus
Hold
17 analysts · average target $8.15 · about 4% above $7.87.
Standalone turnaround bridge
The bid premium is gone. Wendy's valuation now depends on five operational levers: menu quality, value, marketing, execution and digital frequency. Revenue growth is less useful while franchise royalties, traffic and restaurant margins fall.
Material risks
● Trian could revisit a bid, creating sharp volatility.
● Traffic losses directly reduce franchise royalties.
● Higher turnaround spending can delay margin recovery.
● International growth may not offset U.S. weakness.
EarningsNYSE:HRL
Hormel Shares Drop 9.2% After Retail Volume Decline and Lowered Sales Forecast
Hormel Foods stock dropped 9.2% following a decline in retail volume that led to a reset in sales outlook. The fall wiped out roughly…
NYSE: HRL · fiscal Q3 2026
Hormel Foods investor dashboard
Company
Stock move
Packaged food
Market data: Aug. 27, 2026
11:16 a.m. EDT
11:16 a.m. EDT
Share price
$21.52
−9.24% · −$2.19
Market value
$11.86bn
≈−$1.21bn today
Q3 sales
$2.961bn
−2.4% year over year
Adjusted margin
9.0%
+0.6 point
Guidance trade-off: lower sales, higher adjusted floor
The sales midpoint fell $200 million. The midpoint of adjusted EPS guidance increased by one cent, leaving execution and mix as the earnings bridge.
Trading snapshot
| Previous close | $23.71 |
| Open | $23.00 |
| Intraday high | $23.72 |
| Intraday low | $21.45 |
| Volume | 6.05m |
| 3-month average | 4.73m |
| Relative volume | 1.28× |
| Trailing P/E | 25.3× |
| Forward adjusted P/E* | 14.5× |
*Price divided by adjusted EPS guidance midpoint.
Quarterly scorecard
| Metric | Q3 FY26 | YoY |
|---|---|---|
| Net sales | $2.961bn | −2.4% |
| Adjusted operating income | $266m | +4.7% |
| Adjusted operating margin | 9.0% | +0.6 pt |
| Adjusted EPS | $0.37 | +5.7% |
| Operating cash flow | $241m | +54% |
Segment mix
| Segment | Sales | Change |
|---|---|---|
| Retail | $1.779bn | −4% |
| Foodservice | $1.003bn | +2% |
| International | $179m | −5% |
Share of total sales
Retail 60.1%
Foodservice 33.9%
International 6.0%
What moved GAAP earnings
| Discrete pre-tax item | Amount |
|---|---|
| Brazil divestiture loss | $56m |
| Indonesia investment impairment | $48m |
| Litigation settlement | $38m |
| Total | ≈$142m |
GAAP operating income fell 54% to $111 million. Adjusted operating income rose 5%.
Capital and consensus
Cash excluding held-for-sale assets
$840m
Up $169 million from fiscal year-end.
Dividends paid in Q3
$161m
Analyst view
Hold
13 ratings · average target $27.25 · about 27% above $21.52.
Investor read-through
Retail volume fell 9%, making it the central issue. Foodservice grew for a twelfth straight quarter, but it contributes only one-third of sales. The market is pricing a longer path to grocery-volume stabilization despite stronger adjusted margins.
Material risks
● Consumer trade-down can keep retail volume weak.
● Beef, nut, fuel and logistics costs remain volatile.
● Divestitures complicate year-over-year comparisons.
● Foodservice strength may not offset retail scale.
NYSE:CALYStock Market
Callaway Shares Down 1.3% After Retailers Remove Good Good Items in Response to Driver Ad Criticism
CARLSBAD, California, August 27, 2026, 11:18 – Callaway shares fell 1.3% as retailers take Good Good products off shelves, reacting to backlash over a…
NYSE: CALY · Product catalyst
Callaway’s retail-distribution test
A co-branded driver campaign moved from reputational risk to shelf-space risk.
Market data: Aug. 27, 2026
10:54 EDT · regular session
10:54 EDT · regular session
Share price
$15.54
−$0.20 · −1.27%
Range: $15.46–$15.81
Market value
$2.95B
≈$38M erased
Estimate from price change
Q2 equipment sales
$430.3M
+4.5% year over year
70.3% of quarterly sales
Equipment margin
23.3%
+480 bps year over year
Segment operating margin
Investor bridge
The financial question is duration. A brief pause is manageable; a prolonged retail suspension weakens distribution for a segment producing $100.3 million of quarterly operating income.
Financial baseline
| Metric | Q2 2026 | YoY |
|---|---|---|
| Net sales | $612.2M | +2.0% |
| Golf Equipment sales | $430.3M | +4.5% |
| Equipment operating income | $100.3M | +31.6% |
| Adjusted EBITDA | $124.9M | +35.8% |
| Full-year EBITDA outlook | $246M–$260M | Raised Aug. 4 |
What changes next
NowTrack whether Dick’s, Golf Galaxy and PGA Tour Superstore restore Good Good inventory.
Near termWatch Callaway’s investigation, approval-process changes and any partnership reset.
Next reportCompare equipment sell-through and Q3 sales guidance of $415M–$435M.
Risks and sources
Retail reports do not disclose affected units or Callaway’s collaboration revenue. Thursday’s stock decline may reflect broader trading. A rapid restocking could make the financial effect immaterial.
Callaway Q2 results · Company response and product removal · Retailer pullbacks · Analyst consensus
Artificial IntelligenceEarnings
ServiceNow Shares Surge 9%—$11.7 Billion Gain Linked to Salesforce AI Results Shifting Software Valuations
SANTA CLARA, California, August 27, 2026, 10:37 EDT — ServiceNow's stock soared 9%, translating to an added $11.7 billion in market value as Salesforce's…
NYSE: NOW · Stock move
ServiceNow re-rating dashboard
Salesforce's AI results pulled enterprise software higher.
Market snapshot
Aug. 27, 2026 · 10:37 EDT
Aug. 27, 2026 · 10:37 EDT
NOW price
$137.16
+9.03% · +$11.36
Value created
≈$11.7B
Based on 1.03B shares
Volume
10.52M
64.7% of 20-day average by 10:37
Consensus upside
3.7%
$142.23 average target
The gap compressed
What powered the move
Salesforce stock+20.75%
Agentforce + Data 360 ARR$3.9B · +210%
Agentforce ARR>$1.5B · +240%
FY27 revenue outlook$46.1B-$46.4B
Salesforce market data at 10:28 EDT; operating metrics released Aug. 26.
ServiceNow operating engine
Q2 subscription revenue$3.877B · +24.5%
Q2 cRPO$13.20B · +21%
Q2 RPO$29.0B · +21%
FY26 subscription guide$15.760B-$15.780B
FY26 FCF margin guide35%
Valuation and expectations
Market capitalization$141.80B
Forward P/E27.76×
Forward price/sales7.36×
EV/free cash flow28.78×
Analyst ratingStrong Buy · 49 analysts
Software read-through
| Company | Price | Move |
|---|---|---|
| ServiceNow (NOW) | $137.16 | +9.03% |
| Salesforce (CRM) | $248.29 | +20.75% |
| Workday (WDAY) | $197.39 | +3.48% |
| Oracle (ORCL) | $150.84 | +1.32% |
NOW at 10:37 EDT; peer prices at about 10:28 EDT on Aug. 27, 2026.
Near-term checks
2:40 p.m. EDT today
ServiceNow CFO Gina Mastantuono speaks at Deutsche Bank's technology conference.
Next quarter
Watch whether cRPO holds near 20% constant-currency growth and AI ACV converts into subscriptions.
Risk
The rally is a peer read-through. Average target upside is now only 3.7%.
Trend context, correctly dated
The U.S. search phrase “now stock” also points to ServiceNow's expanded Tech Mahindra partnership. It was announced Aug. 20, not today. Tech Mahindra says its ServiceNow deployment handles more than 100,000 monthly cases across 90 countries, supports 150,000 employees and has optimized about 25% of first-level support work.
Revenue and bookings proofValuation re-ratingExecution checkpoint